29 April 2022: Aker BioMarine ASA (“Aker BioMarine” or “the company”) reports revenues of USD 56.9 million and Adjusted EBITDA of USD 8.1 million for the first quarter 2022.
Aker BioMarine Q1 2022 Slide deck
“Aker BioMarine delivers strong growth in our brands segment and record-high harvesting of Antarctic krill in the quarter” said Matts Johansen, CEO of Aker BioMarine. “I am particularly satisfied with the positive development for our US private label and Kori brand. We have also strengthened the Superba krill oil sales organization in all geographies and will execute on our sales pipeline throughout the year to deliver growth. We reiterate our financial targets for the full year 2022.”
Highlights first quarter:
- Revenues of USD 56.9 million, up 14% from the same quarter last year
- Adjusted EBITDA of USD 8.1 million, up 19% from the same quarter last year
- Sales in the Ingredients segment in line with the same quarter last year
- Sales in the Brands segment up 32% from same quarter last year
- Offshore production volume was all-time high at 20,809 tons in the quarter
Aker BioMarine reiterates the targets for 2022 with annual sales growth of between 20-25%, and Adjusted EBITDA margin of 20-25%. The company plans for average annual harvesting volumes of 55,000-60,000 tonnes, although there will be seasonal and operational variations from year to year. The harvesting volume so far in 2022 is about 25,800 tons.
At 09:00 CET today, the management hosts a webcast. Following the presentation, there will be a Q&A session, where written questions can be submitted to ir@akerbiomarine.com.
The webcasted presentation will be in English. To join, please use the link that is available at www.akerbiomarine.com/investor.
A replay of the presentation and Q&A session material will be made available soon after the presentation at the same web address.
For further information, please contact
Carl Christian Bachke, Investor Relations
Mobile: +47 909 808 48
Email: carl.bachke@akerbiomarine.com
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act.
About Aker BioMarine
Aker BioMarine is a leading biotech innovator and Antarctic krill-harvesting company developing krill-derived products for pharma, consumer health and wellness as well as animal nutrition. The company has a strong position in its industry and is the world's leading supplier of krill, the natural, powerful and health promoting source of nutrients from the pristine waters of Antarctica. Aker BioMarine is listed on Oslo Stock Exchange (AKBM). More information is available at www.akerbiomarine.com.